In a deep-dive episode of the 20 minutes VC, host Harry Stebings interviews Matt Oko, co-managing partner and co-founder at Data Collective. They discuss the nuances of venture capital, particularly the impact of fund sizes on investment strategies and the venture lifecycle. Oko argues that strict fund size categorization can destroy valuable early-stage company information and limit societal impact by biasing investment decisions. He also emphasizes the importance of a thesis-driven approach over industry focus, highlighting Data Collective's meta thesis on capital efficiency and defensible algorithms. Furthermore, Oko critiques the traditional ten-year fund lifecycle as too short for maximizing the value of deep tech investments, suggesting a potential need for longer fund durations to allow for the full realization of a company's value.
Hello and welcome back to the 20 minutes VC with your host Harry Stebings. So joining me for this very special show, I'm delighted to welcome Matt Oko. Matt is the co managing partner and co founder at Data Collective and he has over three decades of experience as a tech entrepreneur and VC and has made investments in the likes of Facebook, Zynga, Uber and Angel list, just to name a few.
These quotes introduce the podcast and its host, Harry Stebings, as well as the guest for the episode, Matt Ocko, highlighting his credentials and achievements in the venture capital industry.
It's actually kind of a funny story. We were both at a mutual friend's birthday party back, I don't know, seven, eight years ago. Zach and I ended up sort of talk, yelling at each other about our deep compute and big data investment mutual thesis. One thing led to another, and all of a sudden we had a successful franchise.
These quotes narrate the unconventional founding story of Data Collective, where Matt Ocko and his partner, Zachary Bogue, met and bonded over shared investment interests, leading to the creation of their venture fund.
I sincerely believe, and there's a large but quiet group of other experienced vcs with successful track records who also believe that the strict segregation of funds by size has an information destroying or signal reducing aspect. The later stage investors are now competing with each other on as short a time frame as the early investor can possibly make happen, which means their ability to do complete diligence and to have the most informed possible judgment is reduced. You may not be doing the most interesting, highest returning, most societally or industry transforming company if you're worried that you can't get it past a larger investor.
Matt Ocko articulates his contrarian view that segregating venture capital funds by size leads to a loss of valuable information and signals. He explains how this affects due diligence processes and potentially stifles the funding of transformative companies due to the need to appeal to larger investors' preferences.
Their adjudication of whether that company deserves another 3 million or 5 million or $7 million is at least as good, if not better, than the next guy up the line, especially if that next guy up the line is by necessity deprived of the luxury of time for making a decision.
The quote emphasizes the expertise of early stage investors in making funding decisions and alludes to the time constraints faced by follow-on investors that may affect their judgement.
How do you extricate yourself from that kind of funnel process thinking, and think outside of the box in terms of your investing thesis then?
This question probes the strategy used to avoid conventional investment patterns and to support companies with high potential outside the standard funnel process.
Because if you disagree with conventional wisdom about a series a and you want to write two or three or five or even $7 million in a check yourselves through a company that you believe is extraordinary, you need to have the capacity to do that.
The quote highlights the importance of having sufficient fund size to independently support companies with high conviction, without the need to conform to conventional investment wisdom.
Our opportunity fund is in fact contractually prohibited from chasing deals outside of our portfolio.
This quote describes the strategic limitation placed on the opportunity fund to focus on accelerating the growth of existing portfolio companies.
I don't think that our peers expect us to always follow on from the opportunity fund, because sometimes companies do well enough that they don't need money from the opportunity fund, or sometimes they're growing at a pace where traditional financing is sufficient.
This quote clarifies that the opportunity fund is not expected to always participate in follow-on rounds, as companies may not always need it or may have other financing options.
We are brutally frank with all parties, including the entrepreneurs and the folks upstream, about how we make an investment decision.
The quote stresses the importance of being open and honest about investment decisions, which helps manage expectations and maintain professional relationships.
"Everybody who's invested in Gusto Zenpayroll at almost every stage so far, is going to make a lot of money. We're grateful we had the chance to participate, but I think everybody also respects that we are relentless about our thesis."
This quote highlights the success of Gusto Zenpayroll investments and the firm's commitment to its thesis, which is respected by their investment community.
"Our meta thesis, the thing that we want to see in any company is that they are exemplifying the use of compute and novel, highly defensible algorithms to themselves."
Matt Ocko explains the core of their meta thesis, emphasizing the importance of companies that leverage advanced computing and proprietary algorithms for efficiency and competitive advantage.
"The fact is, in deep tech, in sustainable franchises, not consumer companies, not that consumer companies are bad, but companies with 40 5100 year durability... Those aren't fully realized inside a ten year fund life."
Matt Ocko points out that deep tech companies with long-term potential cannot fully realize their value within the standard fund lifecycle, suggesting a need for change.
"I think that the realization of maximum value from a successful investment and traditional fund lifetimes are beginning to invert."
This quote expresses Ocko's view that the traditional venture fund lifecycles are becoming less aligned with the optimal timeline for realizing the maximum value from investments, particularly in deep tech.
"We measure our companies not by net promoter score, as one of our colleagues likes to talk about, but by how much actual revenue they're making across how many durable Fortune 1000 customers."
Ocko emphasizes the importance of tangible financial success and strong customer relationships with major corporations as key indicators of a company's progress toward market dominance.
"Do I sell positions in a panic to secondary funds? Do I turn off the lights because a company with $150,000,000 of profitable GAAP revenue and a hard paid upfront bookings backlog of $600 million isn't quite ready to go be a victim of aggressive short hedge funds in the public market yet."
Here, Ocko rhetorically questions whether it makes sense to hastily exit investments in profitable companies just because they are not yet ready for the public market, implying a preference for a more patient and strategic approach.
My favorite book is a large volume called the Way Things work, recently updated by the great architect illustrator David McCauley I love it because it's inspired me since childhood and continues to do so by showing intimate details of a huge panoply of human innovation.
Never sleep.
I would, with a joking but ever so slightly sincere rejoinder, say that our returns speak in favor of my strategy and not hers.
There are a handful of founders who are not only superhumanly brilliant, so they process and execute on information an order or more of magnitude faster than you and I.
I rely on the synthesis that I get from nuzzle Jonathan Abrams just fantastic information utility.
So follow on, three scan. Because they are transforming both drug development and medicine by delivering a 3d map from the subcellular level all the way up to complete organ systems 1000 times faster and with essentially infinitely greater accuracy than human pathologists.
They have almost a million discrete companies in 140 countries worldwide, from tiny companies in China up to a huge chunk of the Fortune 100 addicted to their stuff.
But remember, that is not the last we'll be hearing from Matt as we have an incredible second part to this interview, which will be featured in our special AI week, which will discuss the dark and the light side of AI.
You can follow me on Snapchat at htebings with two B's, and you can follow Matt on Twitter at matoko.
So go to Evemattress Co. UK and use the code 20 VC for a fantastic 50 pounds off and it'll be with you in the next day delivery.